Cardiovascular system state changes in non-Hodgkin’s lymphoma patients during chemotherapy
Ay-Suu O-O. Bady, Sof’ya S. Fedorova, Davyd A. Yakhontov, Tat’yana I. Pospelova
Novosibirsk State Medical University of Minzdrav of Russia, Novosibirsk, Russia
arven1951@mail.ru
Keywords: кардиотоксичность, антрациклиновые антибиотики, неходжкинские лимфомы, химиотерапия, доксорубицин, NTproBNP, кардиомиопатия, cardiotoxicity, anthracyclines, non-Hodgkin’s lymphoma, chemotherapy, doxorubicin, NTproBNP, cardiomyopathy
Abstract
Chemotherapy is one of reliable and proven methods of malignant tumor and blood diseases treatment but however the drug side effects (particularly cardiotoxicity) occur. More often cardiovascular complications connect with anthracyclines and related drugs (doxorubicin, daunorubicyn, epirubicyn, idarubicyn, mitoxantron) which usually used at medical scheme because of wide spectrum of action and high effectiveness prescription. Risk of cardiotoxicity formation and existing diseases progression increases according to drug dose, patient’s age, cardiovascular risk factors presence and cardiovascular diseases history. Material and methods. 88 patients with established non-Hodgkin’s lymphoma diagnosis were examined in order to assess cardiovascular system state and pathology nature - 33 patients before chemotherapy and 55 patients in the long-term follow-up period (one year after the start of chemotherapy). Results. It was found that antitumor drugs induced cardiotoxicity may manifest at the beginning of chemotherapy as well as following up period. The cardiac cameras dilation associated with the increase of NTproBNP serum content (N-terminal fragment of natriuretic peptide type B precursor) - the main biomarker of myocardial dysfunction has been revealed by instrumental research.
|
